(Image Credits: Pixabay) Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs). With current ...

Nilotinib, a blood cancer medicine, was previously shown to improve movement and mental function in a small group of patients ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

(WDRB) -- Norton Healthcare's Neuroscience Institute will soon begin offering a non-invasive procedure to reduce tremors in Parkinson's patients ... s disease, according to a news release.

Parkinson’s Disease (PD) is a common brain disorder that affects movement and is most often linked with aging. It’s the second most common age-related brain disease, affecting millions worldwide.

Guo Guangchang, Chairman of Fosun International, remarked, "Over the past seven years, CIIE has improved every year, becoming a window for China to build a new development framework, a platform for ...

Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period ...

Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics: Houston Tuesday, November 5, 2024, 11:00 ...

Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming ...

Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson’s Disease is now fully funded. Favorable capital market conditions last week enabled the company to raise ...